Eli Lilly invites you to an informative session on the management of RET-altered cancers and evolving paradigms in precision oncology. Join Medical Oncologists Dr. Sewanti Limaye, Dr. Krishna Prasad, and Dr. Priya Tiwari as they explore precision oncology with a focus on RET-driven cancers, evolving management strategies, and practical considerations for using selpercatinib in clinical practice. The session will include an interactive Q&A with the experts.

Join us on September 18 , 2026 , from 8:00 PM to 9:00 PM IST to gain practical insights into the management of RET-altered cancers. We look forward to your participation in this thought-provoking session. Agenda : Click here to view Tanstrive PI. This content is approved by Eli Lilly and Company (“Lilly”). This content is the intellectual property of Lilly and its reproduction needs Lilly's prior permission. Website: …